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Objective: In this study, the relationship between circulating transforming growth factor 1 (TGF1) and
urinary albumin excretion (UAE) has been investigated in non-obese and central obese hypertensive
patients. Design and Patients: Fifty-eight consecutive hypertensive outpatients both lean and with central
obesity were enrolled and divided in three groups, according to their body mass index (BMI) values.
Group A: 16 lean hypertensives (men with BMI 25 kg/m2 and women with BMI 24.7 kg/m2); Group
B: 16 overweight hypertensives (men with BMI 25 kg/m2 and 30 kg/m2 and women with BMI
24.7 kg/m2 and27.3 kg/m2); Group C: 26 obese hypertensives (men with BMI30 kg/m2 and women
with BMI 27.3 kg/m2). Measures: In all patients, UAE, by immunonephelometric assay, circulating
TGF1 by a solid-phase specific sandwich enzyme-linked immunosorbent assay (ELISA) technique,
blood urea nitrogen (BUN) and creatinine, by routine laboratory methods, were determined. In addition,
left ventricular telediastolic internal diameter (LVIDd), interventricular septum diastolic (IVSTd),
posterior wall thickness (PWT), total and normalized to height2.7 left ventricular mass (LVM, LVM/h2.7),
relative wall thickness (RWT) and left ventricular ejection fraction (EF) by M-B Mode echocardiography
were calculated. Results: Overweight and obese hypertensives had significantly (p 0.05) higher BMI,
waist–hip ratio (WHR), UAE and TGF1 than lean hypertensives. Obese hypertensives had significantly
(p 0.05) higher total and indexed LVM values than lean hypertensives. Obese hypertensives had
significantly (p 0.05) higher BMI, UAE and TGF1 than overweight hypertensives. In all subjects,
TGF1 correlated directly with BMI (r = 0.52; p 0.0001), WHR (r = 0.48; p 0.003), MBP (r = 0.31;
p 0.02) and UAE (r = 0.57; p 0.0001). Multiple regression analysis indicated that BMI, MBP and
UAE were able to explain the 47.9% TGF1 variability (r = 0.69; p 0.0001), and that TGF1 was the
best predictor of UAE changes (r = 0.60; p 0.0001). Conclusion: Our data suggest that TGF1 levels
are positively associated with BMI, MBP and UAE in hypertensive subjects. This also indicates that
TGF1 overproduction might be considered a pathophysiology mechanism of progressive renal function
impairment in obese hypertensives. Key words: central obesity, hypertension, transforming growth factor
1, urinary albumin excretion.
INTRODUCTION
Hypertension and obesity are disorders that are closed
linked, especially when obesity is characterized by a
central fat distribution. For many years, it has been well
demonstrated that obese patients are more likely to be
hypertensive than lean subjects and that weight gain is
predictive of later onset of hypertension [1, 2]. The two
most important causes of end-stage renal disease are
diabetes mellitus and hypertension, both of which are
closely associated with obesity [3]. Experimental data
indicate that renal haemodynamic and structural change
that occur in obese dogs have some similarities to changes
observed in early type II diabetes mellitus in human
patients [4].
In addition, abnormalities in sodium control and in
renal haemodynamics and function may be early
detectable in normotensive and hypertensive obese
subjects. They include a dysfunction in the renin–
angiotensin system [5], a reduced renal plasma and blood
flow and increased renal vascular resistance [6]. More-
over, microalbuminuria is more frequent in obese than in
lean subjects and in central than in peripheral obese
subjects [6].
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It is well known that an impaired renal function may be
often recognized in hypertensive patients. Additionally, a
relationship between amount of urinary albumin excretion
(UAE) and risk of progression in kidney disease has been
reported in diabetic and hypertensive subjects [7]. In any
case, the final pathway is represented by progressive
sclerosis of glomeruli. Such a main role is played by
transforming growth factor 1 (TGF1), a multifunc-
tional cytokine that regulates cell growth, differentiation,
matrix production [8], blocks matrix degradation [9]
induces fibrosis in many tissues, including kidney, blood
vessels, lung and heart [10]. Data from experimental
studies seem to indicate that high circulating levels of
TGF1 can mediate renal fibrosis and loss of function
[11]. In addition, overproduction of TGF1 has been
found in salt-sensitive rats [12] and it has been involved in
the long-term sequelae of hypertension, including LVH
[13], vascular remodelling [14] and progressive renal
disease [9, 15]. Although these results emphasize the role
of TGF1 overproduction on hypertensive target organ
disease [4, 10, 13–15], so far few data [16] are available
on the relationship between TGF1, degree of obesity and
UAE in hypertensive subjects. Accordingly, the present
study has been designed to evaluate the relationship
between body mass index (BMI), fat distribution,
circulating TGF1 and one of the most important markers
of early renal damage, such as UAE, in a population of
hypertensive subjects. For these reasonscirculating TGF1
and albumin excretion rate were examined in lean,
overweight and obese hypertensive subjects. The princi-
pal aim of the study was to evaluate whether higher levels
of circulating TGF1 were associated with UAE in
obesity-induced hypertension.
PATIENTS AND METHODS
Patients
Fifty-eight consecutive outpatients were enrolled (27
males and 31 females, aged 43–70 years). The patients
were attending antihypertensive centre of the Department
of Internal Medicine at the University of Palermo, Italy.
Subjects were included when blood pressure (average of
three determinations) was greater than 140/90 mmHg on
at least two occasions while the patients were off their
medications [17]. Records of patients taking antihyper-
tensive drugs were reviewed to ascertain the validity of
the diagnosis of hypertension, and patients were included
if blood pressure had been greater than 140/90 mmHg on
two occasions, before treatment. Systolic (SBP) and
diastolic blood pressure (DBP) and mean arterial pressure
(MAP) were taken. MAP was calculated from the
equation [DBP 1/3 (SBP DBP)].
Subjects were defined as overweight and obese based
on their sex-specific 85th percentile of BMI value, as
reported in the Italian consensus conference of obesity
[18].
Accordingly, the men with BMI 25 kg/m2 and
30 kg/m2 and women with BMI 24.7 kg/m2 and
27.3 kg/m2 were considered overweight subjects,
whereas the men with BMI 30 kg/m2 and women with
BMI27.3 kg/m2 were considered obese. In addition, the
men with BMI 25 kg/m2 and women with BMI 24.7
were considered lean subjects. Central fat distribution was
defined based on the sex-specific 85th percentile of waist–
hip ratio (WHR). The cut-off value of central obesity was
considered 0.81 for women and 0.92 for men [18].
Exclusion criteria included secondary hypertension,
diabetes mellitus, cardiovascular diseases (defined as
myocardial infarction, stroke within previous 6 months,
heart failure), endocrinal diseases, renal failure, alcohol-
ism and psychiatric problems. According to BMI values,
all the hypertensive subjects were classified in the
following groups:
Group A (lean hypertensives): 16 subjects (nine females
and seven males; BMI 23 1 kg/m2; WHR
0.8 0.06 cm).
Group B (overweight hypertensives): 16 persons (six
females and 10 males; BMI 28 1 kg/m2; WHR
0.9 0.05 cm).
Group C (obese hypertensives): 26 patients (16 females
and 10 males; BMI 33 5 kg/m2; WHR 0.92 0.06 cm).
Methods
Each patient gave informed consent after receiving a
detailed description of the study procedure. The study was
approved by the Ethics Committee of our Institution.
Patients underwent a general analytical laboratory par-
ameters profile, including urine analysis, blood urea
nitrogen (BUN), creatinine, glycaemia and electrolytes
(serum sodium, potassium, chloride), by routine labora-
tory methods.
UAE
To eliminate the intra-individual day-to-day variability of
UAE, three consecutive 24-h urine collections were used.
In addition, to assess the completeness of a 24-h urine
collection, clearance of creatinine was evaluated. UAE
was measured by immunonephelometric assay (Boehring
Institute; limit of detection, 0.1 mg/dl; inter-assay coeffi-
cient 3.5%). Microalbuminuria was defined as a level of
UAE 30 and 300 mg/24 h.
TGF1
Peripheral venous blood was obtained from each patient
and the sera were isolated and stored at 70°C. TGF1
levels were determined by using a solid-phase specific
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sandwich (R&D Systems, Inc. Minneapolis, Minnesota)
enzyme-linked immunosorbent assay (ELISA) technique
[19]. The interassay and intra-assay variations for
determining TGF1 were 8% and 6%, respectively. The
sensitivity, and hence minimum level of detection of
TGF1 by sandwich ELISA, was 5 pg/ml.
Echocardiography parameters
All patients underwent an echocardiography examination
M and B Mode, by a computerized echocardiography
(ESAOTE, Italy) for the determination of following
parameters: left ventricular telediastolic internal diameter
(LVIDd), interventricular septum diastolic (IVSTd),
posterior wall thickness (PWTd), total left ventricular
mass (LVM) normalized to height2.7 (LVM/h2.7) [20–24].
The relative wall thickness (RWT) by formula [(PWTd/
LVIDd)2] was also calculated. Ejection fraction (EF)
from left ventricular end-diastolic and end-systolic
volumes was measured from the apical four-chamber
view, using the ellipsoidal single-plane algorithm [25].
Mean EF was automatically calculated by the echocardio-
graphic processing system. In our laboratory, the EF
calculated over five consecutive beats permitted optimal
reproducibility and accuracy also in obese subjects [25].
The presence of left ventricular hypertrophy (LVH) was
established when LVM/h2.7 was 51 g/m2.7 for men and
females [20, 26].
Statistical analysis
Differences among three groups were analysed by one-
Table I. Clinical characteristics, renal function, urinary albumin excretion and TGF1 values in lean (Group A),
overweight (Group B) and obese (Group C) hypertensive patients
Group A: Lean, no. 16 Group B: Overweight, no. 16 Group C: Obese, no. 26
Sex (F/M) 9/7 6/10 16/10
Age (years) 46 9 51 3 53 7
BMI (kg/m2) 23 1 28 1a 33 5a
WHR (cm) 0.8 0.06 0.9 0.05 0.92 0.06
SBP (mmHg) 161 16 159 10 168 15
DBP (mmHg) 98 18 91 11 101 15
MBP (mmHg) 119 16 113 10 123 13
UAE (mg/24 h) 150 20 248 21a 450 26ab
BUN (mg/dl) 35 6 37 12 39 10
Creatinine (mg/dl) 0.9 0.2 1 0.2 1 0.2
TGF1 (ng/ml) 2.8 2.1 5 3.2a 7.3 4ab
Minimum 0.87 2.4 3.3
Maximum 7 14.3 19.3
Median 2.1 3.8 5.5
ap 0.05 vs A; bp 0.05 vs B.
Differences of TGF1 among the groups were analysed by Mann–Whitney U test.
TGF1, transforming growth factor (1; BMI: body mass index; WHR, waist–hip ratio; SBP, systolic blood pressure; DBP, diastolic
blood pressure; MBP, mean blood pressure; BUN, blood urea nitrogen; UAE, urinary albumin excretion.
Table II. Left ventricular geometry and function in lean (Group A), overweight (Group B) and obese (Group C)
Group A Group B Group C
LVIDd (mm) 4.7 0.3 4.7 0.3 4.8 0.3
IVSTd (mm) 10.5 1 10.6 1 11.2 2
PWTd (mm) 9 1 9.9 1 10.3 2
RWT [(PWTd/LVIDd)2] 0.37 0.05 0.42 0.07 0.44 0.07
LVM (g) 158 21 174 31 188 48a
LVM/h2.7 (g/m2.7) 41 7 45 10 55 17a
LVEF (%) 62 5 64 6 63 5
%LVH 5/16 (31%) 6/16 (37%) 14/26 (54%)b
a p 0.05 vs A.
bChi square test.
LVIDd, left ventricular internal diastolic diameter; IVSTd, interventricular septum thickness diastolic; PWTd, posterior wall
thickness; RWT, relative wall thickness; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVM/h2.7, left
ventricular mass normalized to height2.7; %LVH, percentage of subjects with left ventricular hypertrophy.
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way analysis of variance and the post-hoc Newman–
Keuls test. Since an asymmetry of TGF1 data distribu-
tion was evident (high skewness), the difference in TGF1
values among the groups were analysed by a non-
parametric test, i.e. Kruskal–Wallis test and by the
Conover–Inman procedure post-hoc test. Differences
among hypertrophic patients’ prevalence of three groups
were analysed by chi-square test. Relationship among
TGF1 and the other parameters were analysed by
univariate and multiple regression analysis. Data are
expressed as mean value  standard deviation (SD). A
p 0.05 was considered statistically significant.
RESULTS
Characteristics of study groups are reported in Tables I
and II. There were no significant differences among the
groups in age and blood pressure values (Table I).
Overweight and obese vs lean hypertensives
Overweight and obese hypertensive patients had signifi-
cantly (p 0.05) higher BMI, WHR, UAE and TGF1
than did lean hypertensives. BUN and creatinine levels
were not significantly different among the groups studied
(Table I).
Fig. 1. Relationship between
transforming growth factor 1,
body mass index (BMI) and
waist–hip ratio (WHR) in all the
subjects studied.
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In addition, obese hypertensive patients had signifi-
cantly (p 0.05) higher total and indexed LVM values
than those detectable in lean hypertensives. An evident,
but not significant, higher prevalence of LVH has been
found only in obese than lean hypertensives (54% vs
31%; Table II).
Obese vs overweight hypertensives
Obese hypertensives had significantly (p 0.05) higher
BMI, UAE and TGF1 than did overweight hyperten-
sives. No significant change in the remaining measure-
ments was found between the two groups (Tables I and
II).
Correlations
In the univariate analysis, there was a positive correlation
between plasma TGF1 concentration and UAE (r = 0.57;
Fig. 2. Relationship between
transforming growth factor 1,
mean blood pressure (MBP) and
urinary albumin excretion (UAE)
in all the subjects studied.
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p 0.0001), BMI (r = 0.52; p 0.0001), WHR (r = 0.48;
p 0.003) and MBP (r = 0.31; p 0.02) (Figs 1 and 2).
No correlation between TGF1 and total and indexed
LVM was found. Multiple regression analysis was used to
investigate relationships between TGF1, UAE and the
other variables. Firstly, for selection of variables, we
analysed the correlation matrix and then TGF1, UAE,
BMI, WHR, LVM/h2.7, MBP, age and gender were
entered into the model. The best subset selection by
examination of all possible regressions was used
computing the minimum Mallow’s Cp statistics. We also
controlled for collinearity and this confirmed the selection
of the variables. Finally, TGF1, UAE, BMI and MBP
were the best variables to fit the model. A regression
equation and the multiple correlation coefficients were
computed. We both controlled for autocorrelation using
the Dubin–Watson test statistic and examined the scatter
plot of the residuals against fitted TGF1 and UAE values
to investigate distributions of data for deviation from
normality. This analysis indicated that BMI, MBP and
UAE were able to explain the 47.9% of TGF1 variability
(r = 0.69; p 0.0001; Table IIIA) and that TGF1 was
the best predictor of UAE changes explain the 36.5% of
UAE variability (r = 0.60; p 0.0001; Table IIIB).
DISCUSSION AND CONCLUSION
The main finding of the current study was the association
among TGF1, UAE and BMI in hypertensive patients.
We found higher TGF1 circulating levels in hyperten-
sive patients with increased BMI as compared with TGF1
levels in hypertensive patients with normal BMI. Our
findings may indicate that an excess of circulating levels
of TGF1 is associated with albumin excretion rate in
central obese hypertensives patients, adding clinical
support to the notion that it plays a role in the
pathophysiology of hypertensive renal disease. This fact
is also supported by a direct relationship between TGF1
levels and one of the most important measurements of
progressive renal damage such as albumin excretion rate.
In our opinion, it is possible to hypothesize that TGF1
overproduction may be considered a pathogenetic mech-
anism for the excess burden of hypertension and
hypertensive renal damage in central obese subjects. In
this context, overproduction of TGF1 has been experi-
mentally linked to the sequelae of chronic hypertension,
including vascular remodelling and progressive renal
disease [27, 28].
In the present study, TGF1 circulating levels were
associated not only with UAE but also with BMI and
WHR, and this strong association was still present after
stepwise multivariate analysis. In addition, our data seem
to indicate that TGF1 may be considered the most
important factor to explain higher UAE levels in central
obese hypertensive subjects. In our opinion, this repre-
sents an interesting finding with relevant clinical
implications, considering the potential role of TGF1,
hypertension, central obesity and UAE rate on cardio-
vascular and tissue organ damage. The exact mechanism
by which TGF1 is enhanced in obese associated
hypertension is not clear, but in this context, it has been
hypothesized that many factors may contribute to TGF1
overproduction. They include a genetic TGF1 DNA
polymorphism [29], angiotensin II activity [30] and shear
stress [31]. Our data extend these studies by demonstrat-
ing an increase of circulating TGF1 in hypertensive,
overweight and obese patients, and suggest a possible
relationship between adipose tissue and TGF1 in vivo
expression. In fact, in our model of multiple regression
analysis, BMI, MBP and UAE globally explain the 48%
of TGF1 variability and TGF1 remained independently
associated with these variables. In our opinion, this strong
association might increase our knowledge of the factors
implicated in the pathophysiology of hypertensive renal
disease in central obese subjects. The progressive increase
of circulating TGF1 levels and UAE in lean, overweight
and obese hypertensive subjects might also suggest an
important role of the degree of obesity for the production
Table III. Multiple regression analysis
(A)
Intercept b0 =14.507853 t =2.673679 p = 0.01
MBP b1 = 0.049135 t = 1.720436 p = 0.09
WHR b2 = 7.859432 t = 1.339088 p = 0.18
BMI b3 = 0.192599 t = 2.316731 p = 0.02
UAE b4 = 5.063598 t = 3.123374 p = 0.002
TGF1 =14.507853 0.049135 MBP 7.859432
WHR 0.192599 BMI 5.063598 UAE.
Analysis of variance from regression: F = 12.194276;
p 0.0001.
Multiple correlation coefficient: R = 0.69; R2 = 47.9%;
Ra2 = 44%.
(B)
Intercept b0 =0.574068 t =1.295463 p = 0.20
WHR b1 = 0.55713 t = 1.215573 p = 0.22
BMI b2 = 0.004673 t = 0.691017 p = 0.49
TGF1 b3 = 0.0307 t = 3.123374 p = 0.003
MBP b4 = 0.000796 t = 0.348741 p = 0.72
UAE =0.574068 0.55713 WHR 0.004673
BMI 0.0307 TGF1 0.000796 MBP.
Analysis of variance from regression: F = 7.620798;
p 0.0001.
Multiple correlation coefficient: R = 0.60; R2 = 36.5%;
Ra2 = 31.7%.
MBP, mean blood pressure; WHR, waist–hip ratio; BMI,
body mass index; UAE, urinary albumin excretion; TGF1,
transforming growth factor 1.
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of TGF1 and for the development of hypertensive renal
disease by a TGF1-dependent pathway. This was
supported by our model of multiple regression analysis
indicating that higher UAE found in obese than lean
hypertensives is largely explained by elevated TGF1
values. This hypothesis is in agreement with previous
experimental data indicating an elevated expression of
TGF1 in the adipose tissue from obese mice [32] and a
direct relationship between BMI and TGF1 in human
adipose tissue [33]. Furthermore, recent data from
Porreca et al. [16] suggest that TGF1 levels are
independently associated with increased BMI and leptin
levels in hypertensive patients. The marked reduction of
TGF1 levels after weight loss induced these authors to
attribute a pivotal role of obesity on TGF1 in vivo
expression.
The biological actions of TGF1 and association with
renal pathology might induce us to speculate that
increased frequency of TGF1 overproduction is a
candidate mechanism for progression of hypertensive
renal disease to end-stage renal function impairment [27].
On the contrary, even if total and normalized LVM
values were significantly higher in obese than lean
hypertensives, no relationship between TGF1 and
LVM was found. In addition, a mild but not significant,
higher prevalence of left ventricular hypertrophy was
observed in obese than in lean hypertensives. This might
indicate a selective role of TGF1 in the pathophysiology
of hypertensive target organ damage [4].
In conclusion, our data are consistent with the
hypothesis that circulating TGF1 overproduction might
be considered an important pathophysiological factor of
hypertensive renal disease above all in central obese
subjects. In view of this, hypertensive subjects with
higher BMI values, central fat distribution and higher
levels of TGF1 may be considered a particular subset of
patients at higher risk of progressive impairment of renal
function. Further longitudinal studies are necessary to
confirm the role of these links on obesity-related renal
consequence of hypertension.
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